Fibrobiologics Financials
This page shows Fibrobiologics (FBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FibroBiologics remains a financing-driven development business, with cash burn led by research and overhead rather than self-funded operations.
From FY2023 to FY2025, R&D spending climbed from$2.4M to$7.4M while financing cash inflows stayed positive each year, so activity has been scaled through capital raises rather than internally generated cash. FY2025's liability drop to$3.5M lifted the current ratio to 3.6x, but cash of$4.9M was only 0.3x that year's operating cash burn.
The relatively small gap between net loss and operating cash flow in FY2024 and FY2025 means the losses are mostly cash losses, not accounting noise:
This is an asset-light but cash-hungry model: FY2025 capital spending was only
Financial Health Signals
Fibrobiologics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Fibrobiologics passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Fibrobiologics reported a net loss of $18.6M while operations used $16.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Fibrobiologics reported an operating loss of $16.6M against $204K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Fibrobiologics's EBITDA was -$16.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.8% from the prior year.
Fibrobiologics reported -$18.6M in net income in fiscal year 2025. This represents a decrease of 67.1% from the prior year.
Fibrobiologics earned -$0.42 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 23.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Fibrobiologics recorded an outflow of $16.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 37.8% from the prior year.
Fibrobiologics held $4.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Fibrobiologics's ROE was -302.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 105.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Fibrobiologics invested $7.4M in research and development in fiscal year 2025. This represents an increase of 64.5% from the prior year.
Fibrobiologics invested $262K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 42.4% from the prior year.
Not reported for fiscal year 2025.
FBLG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| R&D Expenses | N/A | $7.4M+64.5% | $4.5M+90.2% | $2.4M+106.5% | $1.1M |
| SG&A Expenses | N/A | $9.2M+0.1% | $9.2M+41.6% | $6.5M+96.4% | $3.3M |
| Operating Income | N/A | -$16.6M-21.2% | -$13.7M-54.5% | -$8.9M-99.0% | -$4.5M |
| Interest Expense | N/A | $204K+920.0% | $20K-86.4% | $147K-77.5% | $654K |
| Income Tax | N/A | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$18.6M-67.1% | -$11.2M+32.3% | -$16.5M-221.9% | -$5.1M |
| EPS (Diluted) | — | -$0.42-23.5% | -$0.34+50.0% | -$0.68-277.8% | -$0.18 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
FBLG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Total Assets | $9.6M-41.5% | $16.4M+39.1% | $11.8M+145.0% | $4.8M |
| Current Assets | $6.3M-55.4% | $14.2M+54.4% | $9.2M+251.0% | $2.6M |
| Cash & Equivalents | $4.9M-65.0% | $14.0M+52.6% | $9.2M+304.4% | $2.3M |
| Accounts Receivable | N/A | N/A | N/A | $300K |
| Total Liabilities | $3.5M-74.7% | $13.7M+29.7% | $10.6M+19.8% | $8.8M |
| Current Liabilities | $1.8M-86.2% | $12.7M+38.6% | $9.2M+29.8% | $7.1M |
| Total Equity | $6.2M+125.1% | $2.7M+118.3% | $1.3M+131.4% | -$4.0M |
| Retained Earnings | -$54.2M-52.5% | -$35.5M-45.8% | -$24.4M-209.4% | -$7.9M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
FBLG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$14.8M | -$16.4M-37.8% | -$11.9M-85.9% | -$6.4M-57.4% | -$4.1M |
| Capital Expenditures | $6K | $262K+42.4% | $184K-62.8% | $495K | N/A |
| Free Cash Flow | -$14.8M | -$16.7M-37.8% | -$12.1M-75.2% | -$6.9M | N/A |
| Investing Cash Flow | -$6K | -$262K-42.4% | -$184K+62.8% | -$495K | N/A |
| Financing Cash Flow | $9.5M | $7.6M-55.3% | $16.9M+22.6% | $13.8M+132.8% | $5.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
FBLG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Return on Equity | -302.9%+105.2pp | -408.1%+907.6pp | -1315.6% | N/A |
| Return on Assets | -193.8%-126.0pp | -67.9%+71.6pp | -139.5%-33.3pp | -106.2% |
| Current Ratio | 3.61+2.5x | 1.12+0.1x | 1.00+0.6x | 0.37 |
| Debt-to-Equity | 0.56-4.5x | 5.01-3.4x | 8.43 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Fibrobiologics Ranks
Frequently Asked Questions
Is Fibrobiologics profitable?
No, Fibrobiologics (FBLG) reported a net income of -$18.6M in fiscal year 2025.
What is Fibrobiologics's EBITDA?
Fibrobiologics (FBLG) had EBITDA of -$16.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Fibrobiologics's return on equity (ROE)?
Fibrobiologics (FBLG) has a return on equity of -302.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Fibrobiologics's free cash flow?
Fibrobiologics (FBLG) recorded an outflow of $16.7M in free cash flow during fiscal year 2025. This represents a -37.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Fibrobiologics's operating cash flow?
Fibrobiologics (FBLG) recorded an outflow of $16.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Fibrobiologics's total assets?
Fibrobiologics (FBLG) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Fibrobiologics's capital expenditures?
Fibrobiologics (FBLG) invested $262K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Fibrobiologics spend on research and development?
Fibrobiologics (FBLG) invested $7.4M in research and development during fiscal year 2025.
What is Fibrobiologics's current ratio?
Fibrobiologics (FBLG) had a current ratio of 3.61 as of fiscal year 2025, which is generally considered healthy.
What is Fibrobiologics's debt-to-equity ratio?
Fibrobiologics (FBLG) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Fibrobiologics's return on assets (ROA)?
Fibrobiologics (FBLG) had a return on assets of -193.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Fibrobiologics's cash runway?
Based on fiscal year 2025 data, Fibrobiologics (FBLG) had $4.9M in cash against an annual operating cash burn of $16.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Fibrobiologics's Piotroski F-Score?
Fibrobiologics (FBLG) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Fibrobiologics's earnings high quality?
Fibrobiologics (FBLG) reported a net loss of $18.6M while operations used $16.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Fibrobiologics cover its interest payments?
Fibrobiologics (FBLG) reported an operating loss of $16.6M against $204K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.